Anti-HA Antibody Market Size & Share, by Type (IgM, IgG, IgA); Application (Therapeutic, Research, Diagnostic); End-User (Hospitals, Diagnostic Centers, Research Institutes, Biopharmaceutical Companies); Distribution Channel (Direct Sales, Distributors) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5461
  • Published Date: Dec 18, 2023
  • Report Format: PDF, PPT

Companies Dominating the Anti-HA Antibody Landscape

    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Johnson & Johnson
    • Merck KGaA
    • Novartis International AG
    • AbbVie Inc.
    • Amgen Inc.
    • Pfizer Inc.
    • Bayer AG
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company

Browse Key Market Insights with Data Illustration:


In The News

  • Pfizer Inc. and BioNTech SE released positive topline outcomes from a Phase 1/2 study (NCT05596734) analyzing the protection, acceptability, and immunogenicity of mRNA-dependent mixture vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. The information from the investigation demonstrated that the organizations' lead preparation showed powerful immune replies to influenza A, influenza B, and SARS-CoV-2 strains.
  • Pfizer Inc. presented information across its contagious disease portfolio at IDWeek 2023 occurred in Boston from October 11-15, 2023. Information from 45 abstracts shows the developments Pfizer is making in helping stop and cure specific contagious diseases, specifically respiratory illnesses. This comprised research highlighted in the IDWeek press program analyzing the possible public health influence of ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the organization’s double respiratory syncytial virus prefusion F (RSVpreF) vaccine for motherly immunization to safeguard infants against RSV illness.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5461
  • Published Date: Dec 18, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing cases of influenza flu in people worldwide will majorly drive the market growth of the anti-HA antibody market.

The market size of the anti-HA antibody market is expected to get a CAGR of approximately 7% over the forecast period, i.e., 2024-2036.

The major players in the market are F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck KGaA, Novartis International AG, AbbVie Inc., Amgen Inc., Pfizer Inc., Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb Company, Daiichi Sankyo Co Ltd, Takeda Pharmaceutical Co Ltd., Chugai Pharmaceutical Co Ltd, Sanofi KK.

The IgM segment is anticipated to reap the largest market size with almost 47% by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying